Galectin-3 as a Prognostic Biomarker in Patients with First Acute Myocardial Infarction without Heart Failure

Round 1

Reviewer 1 Report

Comments and Suggestions for Authors

I congratulate the authors for this very interesting article. The authors investigated the prognostic value of Galectin-3 (Gal-3) plasma concentration in patients who had experienced acute myocardial infarction (AMI) with preserved ejection fraction. Their research suggests that Gal-3 levels, particularly when measured from the aortic root, could be a useful indicator for predicting adverse cardiovascular events in patients who have experienced AMI. Further studies with larger sample sizes may help validate these findings and explore potential therapeutic implications.

I have a very few comments (in no order of magnitude)

·        In Table 2 CAD abbreviation is missing

·        In the introduction, Galectin-3 (Gal-3) is ‘a’ member of lectin family..  

·        On page 8, ‘The’ Prognostic value of Gal-3.

·        On page 9, All of the above-mentioned studies ‘corroborate’ our findings.

·        On page 9, This could be ‘an’ aim for future investigations

·        PICP is associated with increased myocardial fibrosis/activated fibroblasts, which is the major source of Gal-3. If the authors still have samples available to probe, then it will interesting to see the correlation of  PICP to Gal-3 in patients with MACE.

·        A few other articles can be included in the discussion.

Short and Long-Term Prognostic Significance of Galectin-3 in Patients with ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention (PMID-36594728)

“Galectin-3 Regulates Atrial Fibrillation Remodeling and Predicts Catheter Ablation Outcomes” (PMID- 27525318)

 

Author Response

Dear reviewer, 

thank you for suggestion. We corrected manuscript. 

Author Response File: Author Response.pdf

Reviewer 2 Report

Comments and Suggestions for Authors

The manuscript authored by Vucic et al. demonstrated galectin-3 as a prognostic marker for the progression of heart failure in acute myocardial infarction patients. The data strongly substantiate the observations made in the manuscript.

 I have the following comments on the manuscript:

 If available, please include cardiac echo image data for the patients, as this could provide valuable insights into the study's context and findings.

It would greatly enhance the manuscript's quality and relevance to clinical practice if you could include a paragraph discussing the clinical significance of the study. Explain what new information it brings to the field and how it can contribute to clinical decision-making.

 

Author Response

Dear reviewer, 

thank you for suggestions. We corrected manuscript. 

Author Response File: Author Response.pdf